Vitiligo.

Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study. N Engl J Med (1997) 2.98

A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. Arch Dermatol (2003) 2.00

Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res (2003) 1.90

The development of guidelines for the treatment of vitiligo. Clinical Epidemiology Unit of the Istituto Dermopatico dell'Immacolata-Istituto di Recovero e Cura a Carattere Scientifico (IDI-IRCCS) and the Archives of Dermatology. Arch Dermatol (1999) 1.73

Vitiligo. Pathogenesis and treatment. Am J Clin Dermatol (2001) 1.68

Treatment of vitiligo with UV-B radiation vs topical psoralen plus UV-A. Arch Dermatol (1997) 1.62

An epidemiologic case-control study in a population with vitiligo. J Am Acad Dermatol (1995) 1.61

Coping with the disfiguring effects of vitiligo: a preliminary investigation into the effects of cognitive-behavioural therapy. Br J Med Psychol (1999) 1.48

The relationship between stress and the onset and exacerbation of psoriasis and other skin conditions. Br J Dermatol (1994) 1.45

Parametric modeling of narrowband UV-B phototherapy for vitiligo using a novel quantitative tool: the Vitiligo Area Scoring Index. Arch Dermatol (2004) 1.42

Treatment of vitiligo with 0-1 per cent betamethasone 17-valerate in isopropyl alcohol--a double-blind trial. Br J Dermatol (1974) 1.28

Association of the Köbner phenomenon with disease activity and therapeutic responsiveness in vitiligo vulgaris. Arch Dermatol (1999) 1.25

Oral mini-pulse therapy with betamethasone in vitiligo patients having extensive or fast-spreading disease. Int J Dermatol (1993) 1.25

Vitiligo and other diseases: coexistence or true association? Hamburg study on 321 patients. Dermatology (1994) 1.22

Vitiligo. What is it? Is it important? JAMA (1978) 1.21

Autoantibodies in patients with vitiligo. Lancet (1969) 1.16

Novel vitiligo susceptibility loci on chromosomes 7 (AIS2) and 8 (AIS3), confirmation of SLEV1 on chromosome 17, and their roles in an autoimmune diathesis. Am J Hum Genet (2004) 1.15

Squamous cell carcinoma in a patient with generalized vitiligo. J Am Acad Dermatol (2001) 1.14

Nonsurgical repigmentation therapies in vitiligo. Meta-analysis of the literature. Arch Dermatol (1998) 1.13

Oral dexamethasone pulse treatment for vitiligo. J Am Acad Dermatol (2001) 1.11

New insights and new therapies in vitiligo. JAMA (2005) 1.09

PUVA and cancer risk: the Swedish follow-up study. Br J Dermatol (1999) 1.02

A genomewide screen for generalized vitiligo: confirmation of AIS1 on chromosome 1p31 and evidence for additional susceptibility loci. Am J Hum Genet (2003) 0.99

Association of HLA-DR4 with vitiligo. J Am Acad Dermatol (1983) 0.97

Effect of topical calcipotriol, betamethasone dipropionate and their combination in the treatment of localized vitiligo. J Eur Acad Dermatol Venereol (2006) 0.94

Psychological reaction to chronic skin disorders: a study of patients with vitiligo. Gen Hosp Psychiatry (1979) 0.93

Comparison of 0.05% clobetasol propionate cream and topical Puvasol in childhood vitiligo. Int J Dermatol (1995) 0.91

Left-right comparison study of the combination of fluticasone propionate and UV-A vs. either fluticasone propionate or UV-A alone for the long-term treatment of vitiligo. Arch Dermatol (1999) 0.89

Dendritic cell dynamics in progressive depigmentations. Distinctive cytokinetics of -dendritic cells revealed by electron microscopy. Arch Dermatol Forsch (1972) 0.88

Treatment of generalized vitiligo in children with narrow-band (TL-01) UVB radiation therapy. J Am Acad Dermatol (2000) 0.88

Treatment of vitiligo vulgaris with narrow band UVB (311 nm) for one year and the effect of addition of folic acid and vitamin B12. Acta Derm Venereol (2002) 0.87

Efficacy and safety of pimecrolimus cream 1% in adult patients with vitiligo: results of a randomized, double-blind, vehicle-controlled study. J Dtsch Dermatol Ges (2006) 0.85

Detection of antibodies to melanocytes in vitiligo by specific immunoprecipitation. J Invest Dermatol (1983) 0.85

PUVA therapy for psoriasis: comparison of oral and bath-water delivery of 8-methoxypsoralen. J Am Acad Dermatol (1986) 0.85

Guidelines of care for vitiligo. American Academy of Dermatology. J Am Acad Dermatol (1996) 0.85

Impact of life events on the onset of vitiligo in adults: preliminary evidence for a psychological dimension in aetiology. Clin Exp Dermatol (1998) 0.85

Narrow-band ultraviolet B as monotherapy and in combination with topical calcipotriol in the treatment of vitiligo. J Dermatol (2006) 0.84

Tacalcitol and narrow-band phototherapy in patients with vitiligo. Clin Exp Dermatol (2006) 0.84

A double-blind trial of 0-05% clobetasol proprionate in the treatment of vitiligo. Br J Dermatol (1977) 0.84

The treatment of vitiligo with topical corticosteroids. Light and electronmicroscopic studies. Br J Dermatol (1976) 0.83

The treatment of vitiligo with psoralens and triamcinolone by mouth. Br J Dermatol (1967) 0.83

Genetic nature of vitiligo. J Dermatol Sci (1992) 0.82

Successful treatment of vitiligo with 0.1% tacrolimus ointment. Arch Dermatol (2003) 0.82

PUVA and PUVB in vitiligo--are they equally effective? Photodermatol Photoimmunol Photomed (2001) 0.81

Vitiligo. An overview of therapeutic approaches. Dermatol Clin (1993) 0.79

Safety and therapeutic effectiveness of 8-methoxypsoralen, 4,5',8-trimethylpsoralen, and psoralen in vitiligo. Natl Cancer Inst Monogr (1984) 0.79

A randomized placebo-controlled double-blind study of levamisole in the treatment of limited and slowly spreading vitiligo. Br J Dermatol (2005) 0.79

Therapeutic success of epidermal grafting in generalized vitiligo is limited by the Koebner phenomenon. J Am Acad Dermatol (1990) 0.78

No additional effect of topical calcipotriol on narrow-band UVB phototherapy in patients with generalized vitiligo. Photodermatol Photoimmunol Photomed (2005) 0.78

The provocation of cutaneous disease; Köbner's isomorphic phenomenon. Arch Middx Hosp (1951) 0.78

Guidelines for the treatment of vitiligo. Drugs (1992) 0.78

Is the efficacy of psoralen plus ultraviolet A therapy for vitiligo enhanced by concurrent topical calcipotriol? A placebo-controlled double-blind study. Br J Dermatol (2001) 0.78

[4-5-8 trimethylpsoralen in vitiligo. Controlled study of its therapeutic and toxic effect in children]. Actas Dermosifiliogr (1976) 0.77

Treatment of vitiligo by local application of betamethasone 17-valerate in a dimethyl sulfoxide cream base. Dermatologica (1973) 0.77

Treatment of vitiligo by topical calcipotriol. J Eur Acad Dermatol Venereol (2002) 0.77

A clinical trial of clobetasol propionate in Filipino vitiligo patients. Clin Ther (1987) 0.77